IP Library › Patent Application 17968161
Patent Application
App. No. 17/968,161

SPORE-BASED PROBIOTIC COMPOSITION FOR REDUCTION OF DIETARY ENDOTOXEMIA AND RELATED METHODS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/968,161
Abstract

A method of treating metabolic endotoxemia comprising identifying a subject having post-prandial dietary endotoxemia and administering an effective amount of a spore-based probiotic. While any spore-based probiotic may be used, the probiotic supplement may comprise Bacillus indicus (HU36), Bacillus subtilis (HU58), Bacillus coagulans, Bacillus licheniformis , and Bacillus clausii . One or more of a level of blood endotoxin, triglyceride, post-prandial insulin, post-prandial ghrelin level, MCP-1, GM-CSF, IL-12p70, IL-13, IL-1beta, IL-4, IL-5, IL-6, IL-7, IL-8, and TNF-α is observed as being lower after spore-based probiotic supplementation when compared to placebo. At least one of post-prandial leptin and IL-10 is observed as being higher after spore-based probiotic supplementation when compared to placebo.

Claims (21)

1 - 22 . (canceled)

23 . A method of treating metabolic endotoxemia comprising:

administering to a subject in need thereof an effective amount of a spore-based probiotic, wherein the spore-based probiotic comprises spores consisting of Bacillus indicus HU36, Bacillus subtilis HU58, Bacillus coagulans, Bacillus licheniformis , and Bacillus clausii.

24 . The method of claim 23 , wherein the level of at least one of postprandial insulin, post-prandial ghrelin, or MCP-1 is reduced.

25 . The method of claim 23 , wherein the level of at least one of GM-CSF, IL-12p70, IL-13, IL-I beta, IL-4, IL-5, IL-6, IL-7, IL-8, or TNF-α is reduced.

26 . The method of claim 23 , wherein the level of at least one of postprandial leptin or IL-10 is increased.

27 . The method of claim 23 , wherein the spore-based probiotic comprises spores having a survival rate between about 75% and 99% after exposure to gastric acid.

28 . The method of claim 23 , wherein the spore-based probiotic comprises spores having a survival rate greater than about 90% after exposure to gastric acid.

29 . The method of claim 23 , wherein the spore-based probiotic is in at least one of a liquid form, a pill form and a food product form.

30 . The method of claim 23 , wherein the subject experiences at least one of a reduction in triglyceride and a post-prandial reduction of an endotoxin after administration of the effective amount of the spore-based probiotic.

31 . The method of claim 30 , wherein the endotoxin comprises lipopolysaccharide (LPS).

32 . A method of reducing a post-prandial blood endotoxin level comprising:

administering to a subject in need thereof an effective amount of a spore-based probiotic, wherein the spore-based probiotic comprises spores consisting of Bacillus indicus HU36, Bacillus subtilis HU58, Bacillus coagulans, Bacillus licheniformis , and Bacillus clausii.

33 . The method of claim 32 , wherein the spore-based probiotic comprises spores having a survival rate between about 75% and 99% after exposure to gastric acid.

34 . The method of claim 32 , wherein the spore-based probiotic comprises spores having a survival rate greater than about 90% after exposure to gastric acid.

35 . The method of claim 32 , wherein the level of at least one of an endotoxin or a triglyceride is reduced in the subject after administration of the effective amount of the spore-based probiotic.

36 . The method of claim 35 , wherein the endotoxin comprises lipopolysaccharide (LPS).

37 . The method of claim 32 , wherein the level of at least one of post-prandial insulin, post-prandial ghrelin, or MCP-1 is reduced after administration of the effective amount of the spore-based probiotic.

38 . The method of claim 32 , wherein the level of at least one of GM-CSF, IL-12p70, IL-13, IL-I beta, IL-4, IL-5, IL-6, IL-7, IL-8, or TNF-α is reduced after administration of the effective amount of the spore-based probiotic.

39 . The method of claim 32 , wherein the level of at least one of post-prandial leptin or IL-10 is increased after administration of the effective amount of the spore-based probiotic.

40 . The method of claim 32 , wherein the spore-based probiotic is in at least one of a liquid form, a pill form, and a food product form.